Dulaglutide

Key Benefits#

• FDA-approved for type 2 diabetes
• Once-weekly subcutaneous dosing via auto-injector pen
• Reduces HbA1c by approximately 1.1–1.6%
• Modest weight loss of 1.5–3 kg at approved doses
• Demonstrated cardiovascular risk reduction (REWIND trial)
• Established long-term safety profile
• Renal protective effects in CKD

Mechanism of Action#

Dulaglutide activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion while suppressing glucagon. It slows gastric emptying and acts centrally in the hypothalamus to reduce appetite. The IgG4 Fc fusion extends half-life significantly compared to native GLP-1, enabling once-weekly dosing. REWIND demonstrated a 12% reduction in MACE (major adverse cardiovascular events) in patients with or at risk for cardiovascular disease.

Dosing Protocols#

Side Effects#

• Nausea (most common, typically transient)
• Diarrhea
• Vomiting
• Decreased appetite
• Abdominal pain
• Risk of thyroid C-cell tumors (rodent data — black box warning)
• Pancreatitis (rare)

Contraindications#

Personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Severe gastrointestinal disease. Type 1 diabetes or diabetic ketoacidosis.

Storage#

Refrigerate at 2–8°C. May store at room temperature (≤30°C) for up to 14 days. Protect from light.

1. 1.
   Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin

   Pavlidis G, Prentza V, Ikonomidis I, Katogiannis K, Kountouri A, Thymis J et al. · Medicina (Kaunas, Lithuania) · 2026PubMed Verified

2. 2.
   Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study

   Guo M, Chen S, Dong H, Cai M, Guo M, Cheng H · Naunyn-Schmiedeberg's archives of pharmacology · 2026PubMed Verified

3. 3.
   Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study

   Hsu HY, Shi HY · Diabetes research and clinical practice · 2026PubMed Verified

4. 4.
   Dulaglutide Effect on Proteins Associated With CKD Progression

   McFarlin BE, Tye SC, Satake E, Md Dom ZI, Kechter A, Wilson JM et al. · Kidney international reports · 2026PubMed Verified

5. 5.
   A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management

   Chen Q, Chen T, Lin W, Chen X · Diabetes, metabolic syndrome and obesity : targets and therapy · 2026PubMed Verified

6. 6.
   Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status

   Ulrich FS, Napoli N, Nielsen MF, Burden AM · Diabetes, obesity & metabolism · 2026PubMed Verified

7. 7.
   GLP-1 and the cardiovascular system

   Kahles F, Birkenfeld AL, Marx N · The Journal of clinical investigation · 2026ReviewPubMed Verified

8. 8.
   Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov

   Patil S, Jha N, Jha MK · Addictive behaviors reports · 2026PubMed Verified

9. 9.
   Case study on adverse reactions of dulaglutide: literature review

   Zhou Y, Jiang W · Frontiers in pharmacology · 2026PubMed Verified

10. 10.
    Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents

    Shevchouk O, Edvardsson CE, Ericson M, Blid Sköldheden S, Zhang Q, Dreher Nabinger D et al. · Behavioural brain research · 2026PubMed Verified

11. 11.
    Dulaglutide and pregnancy: a comprehensive safety assessment using the ex vivo placenta perfusion and in vitro models

    Kuoni S, Caviglia S, Dolder A, Gawinecka J, Ochsenbein-Kölble N, Simões-Wüst AP · Frontiers in pharmacology · 2025PubMed Verified

12. 12.
    Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice

    Kubota-Okamoto S, Kubota S, Tsuchida H, Liu Y, Banno S, Imaizumi T et al. · Journal of diabetes investigation · 2026PubMed Verified

13. 13.
    Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes

    Hsiao FC, Hsu TJ, Hsieh YJ, Tung YC, Chen DY, Lin CP et al. · JAMA network open · 2026PubMed Verified

14. 14.
    Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis

    Ailawadi S, Murphy JE, Storandt MH, Mahipal A · Cancers · 2026PubMed Verified

15. 15.
    A cardiovascular indication for oral semaglutide (Rybelsus)

    The Medical letter on drugs and therapeutics · 2025PubMed Verified

16. 16.
    Correction to "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes"

    Pharmacoepidemiology and drug safety · 2026PubMed Verified

17. 17.
    Calculating cost per event avoided using a composite number needed to treat

    Toliver J, Wang J, Bhavsar J, Sullivan SD · Journal of medical economics · 2026PubMed Verified

18. 18.
    Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?

    Centor RM, Alkabbani W · Annals of internal medicine · 2026PubMed Verified

19. 19.
    Clinical Presentation of a Child With a Novel ALMS1 Variant Associated With Alström Syndrome and Favorable Response to GLP-1 Receptor Agonist Therapy

    Alvarez G, Huang A, Grody WW, Yazdani S · American journal of medical genetics. Part A · 2026Case ReportPubMed Verified

20. 20.
    Effects of GLP-1 receptor agonists on copeptin in euvolemic participants

    Leibnitz S, Winzeler B, Refardt J, Vogt DR, Sailer CO, Christ-Crain M · European journal of endocrinology · 2026RCTPubMed Verified

21. 21.
    Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management

    Riccioni G, Notarangelo C, Riccioni M, D'Orazio N · International journal of molecular sciences · 2025ReviewPubMed Verified

22. 22.
    Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study

    Jeon M, Hong B, Ko HY, Song HJ, Kwak SH, Kim JH et al. · Diabetes research and clinical practice · 2026PubMed Verified

23. 23.
    Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

    Tan X, Liang Y, Xie L, Harton J, Gutierrez C, Muhammad C et al. · Diabetes, obesity & metabolism · 2026PubMed Verified

24. 24.
    Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review

    Deameh MG, Ramez M, Rowaiee R, Bani Irshid BA, Mohamed H, Abdelshafi A et al. · The journal of sexual medicine · 2026Meta-AnalysisPubMed Verified

25. 25.
    Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024

    Fat MN, Johnson HC, Farberg AS · Journal of drugs in dermatology : JDD · 2026PubMed Verified

26. 26.
    Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes

    Miramontes-González JP, Rodrigo-Alaíz Á, Gabella-Martín M, González-Calle D, Carretero-Gómez J, Corral-Gudino L · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026ReviewPubMed Verified

27. 27.
    Unmasking the risk: euglycemic diabetic ketoacidosis induced by GLP-1 agonist in type 2 diabetes

    Adrejiya P, Alhujaily E, Abubaker M, Dorenbush C, Khouzam R · Proceedings (Baylor University. Medical Center) · 2026Case ReportPubMed Verified

28. 28.
    GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization

    Mahadevan A, Vosooghi A, Arora JS, Kumar RS, Singh G, Tsai KK et al. · The Journal of clinical endocrinology and metabolism · 2026PubMed Verified

29. 29.
    Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process

    Shaifutdinov RR, Sinegubova MV, Vorobiev II, Prokhorova PE, Podkorytov AB, Orlova NA · Pharmaceuticals (Basel, Switzerland) · 2025PubMed Verified

30. 30.
    Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols

    Davila Diaz R, Campos Barrera E, Diaz Fosado LA, Reyes Esparza A, Perez Benitez OA · Cureus · 2025ReviewPubMed Verified

31. 31.
    Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

    Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H et al. · Nature · 2025PubMed Verified

32. 32.
    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

    Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE et al. · The New England journal of medicine · 2025Clinical TrialPubMed Verified

33. 33.
    Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence

    Taj S, Zuber M, Rashid M, Chhabra M, Undela K, Rawal S et al. · Diabetes, obesity & metabolism · 2026Meta-AnalysisPubMed Verified

34. 34.
    Real-World Evidence of Long-Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years

    Kim HS, Kim MJ, Kim HS, Cho YK, Jung CH, Lee WJ · Clinical endocrinology · 2025PubMed Verified

35. 35.
    Changes in fibroblast growth factor 21 levels associated with alcohol consumption and smoking cessation

    Sailer CO, Vogel CF, Monnerat S, Probst L, Christ-Crain M, Winzeler B et al. · Endocrine connections · 2026PubMed Verified

36. 36.
    Glucagon-Like Peptide 1 Receptor Agonist Use and Vertebral Fracture Risk in Type 2 Diabetes

    Khor WT, Chi KY, Lin HM, Chang Y · JAMA surgery · 2026PubMed Verified

37. 37.
    Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis

    Rai A, Kolli M, Singh GP, Rishu, Li Cai CY, Balaji H et al. · Cureus · 2025ReviewPubMed Verified

38. 38.
    Stroke and Diabetes in Adults

    Lawrence JM, Casagrande SS, Herman WH, Wexler DJ, Cefalu WT, Chen C et al. · 2023ReviewPubMed Verified

39. 39.
    Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes

    Hong AT, Lin F, Baxter S, Weinreb RN · American journal of ophthalmology · 2026PubMed Verified

40. 40.
    The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis

    Tseng PT, Zeng BY, Hsu CW, Suen MW, Hung CM, Carvalho AF et al. · Journal of the Royal Society of Medicine · 2025PubMed Verified

41. 41.
    GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge

    Mani K · Journal of diabetes and metabolic disorders · 2025PubMed Verified

42. 42.
    Acute Pancreatitis After Initiating Dulaglutide in a Patient Previously Treated With a DPP-4 Inhibitor: Case Report From Palestine

    Nasser A, Ladadweh H, Madia R, Dalashi A, Wahdan A, Alawi A · Case reports in gastrointestinal medicine · 2025Case ReportPubMed Verified

43. 43.
    Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report

    Itsathitpaisarn R, Suksawad N, Wongwikrom W, Surintrspanont J, Thongsricome T · The American journal of case reports · 2025Case ReportPubMed Verified

44. 44.
    GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study

    Gonzalez F, Reid MW, Garcia JF, Raymond JK, Chao LC · Journal of pediatric endocrinology & metabolism : JPEM · 2026PubMed Verified

45. 45.
    The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis

    Sinha B, Ghosal S · Addiction science & clinical practice · 2025Meta-AnalysisPubMed Verified

46. 46.
    Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism

    Motegi S, Adachi M, Nagahara K, Ochi A, Ishida T, Mizuno K · JCEM case reports · 2026Case ReportPubMed Verified

47. 47.
    Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes

    Bonnesen K, Heide-Jørgensen U, Christensen DH, Lash TL, Pedersen L, Thomsen RW et al. · Pharmacoepidemiology and drug safety · 2025PubMed Verified

48. 48.
    GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians

    Saha B, Kamalumpundi V, Codipilly DC · Mayo Clinic proceedings · 2025ReviewPubMed Verified

49. 49.
    Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis

    Eshraghi R, Ghadimi DJ, Montazerinamin S, Bahrami A, Kachela Y, Rezasoltani M et al. · EClinicalMedicine · 2025PubMed Verified

50. 50.
    Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review

    Zacharia GS, Gongati SR, Kharel A, Jacob A · Cureus · 2025ReviewPubMed Verified